The Metal-Targeted Therapy and Immunology Lab at the Children's Cancer Institute NSW has identified a strong connection between copper transporters found in malignant cancer tissue compared with normal tissue (copper transporter 1 CTR-1 and PD-L1). Their cutting-edge research is the first to prove that chelation therapy enhances anti-tumour immune responses and could be repurposed for immune checkpoint inhibition.
Dr Vittorio will present crucial evidence from their research using an FDA-approved copper chelator to increase tumour infiltrating immune cells and improve the survival in a neuroblastoma immunocompetent mouse model.
Dr Orazio Vittorio
University of New South Wales, Children's Cancer Institute
Dr Vittorio is a NHMRC Career Development Fellow and Scientia Senior Lecturer with the Faculty of Medicine at the University of New South Wales. He is head of the Metal-Targeted Therapy and Immunology Lab at the Children's Cancer Institute. Dr Vittorio is cancer biologist with ten years of post-doctoral experience and an emerging international reputation in the development of anti-cancer therapeutics. He consistently publishes research that is highly influential. Dr Vittorio has published more than 84 papers in international journals, six book chapters and four patents.
Monday 12 October 2020
This event will be hosted via the Zoom platform. Zoom is accessible on your computer, tablet or phone via the Zoom app. If you have any issues with this platform on your device, please visit the Zoom support site. Alternatively please contact your IT administrator.